June 3 (Reuters) - Structure Therapeutics said on Monday its obesity drug candidate helped achieve average weight loss of 6.2% in a mid-stage study.

Shares of Structure rose about 38% to $47.03 in premarket trading.

In a separate study, the drug's new tablet formulation showed mean weight loss of up to 6.9% at 12 weeks of treatment, Structure said.

Structure's once-daily drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's blockbuster weight-loss drug Wegovy and Eli Lilly's Zepbound. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)